Text Size

Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety

Takagi Y., Osaki H., Yamashita T., Kai Y.


  • 2016
  • Ophthalmology and Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Scientific Information Group, Santen Pharmaceutical Co., Ltd, Ofukacho Kita-ku, Osaka, Japan; Safety Vigilance Group, Santen Pharmaceutical Co., Ltd, Ofukacho Kita-ku, Osaka, Japan

Related Publications

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.


24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM


MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022